Login Register Cart 0
Generic placeholder image

Current Pharmacogenomics and Personalized Medicine

Editor-in-Chief

ISSN (Print): 1875-6921
ISSN (Online): 1875-6913

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Investigating the Association of rs4962416 and rs6465657 with Prostate Adenocarcinoma in the Iranian Population

Author(s): Tannaz Hemmati, Seyed Abdolhamid Angaji*, Behnaz Beikzadeh, Hengameh Alibeik, Raheleh Roudi and Behzad Narouie

Volume 20, Issue 2, 2023

Published on: 31 August, 2023

Page: [116 - 127] Pages: 12

DOI: 10.2174/1875692120666230816150545

Price: $65

Abstract

Background: Prostate cancer is one of the most commonly diagnosed malignancies in the developed world. Despite other risk factors like age, diet, environment and the pathogenesis of prostate cancer, recent advances in molecular genetics suggest that genetic inheritance plays an important role in prostate cancer.

Objective: We attempted to analyze the association of SNPs rs4962416 and rs6465657 in the development of prostate cancer. A better understanding of the association of SNPs in prostate cancer susceptibility may improve risk prediction, improve precision mapping, and provide new insights into the underlying pathophysiology of prostate cancer. To date, no one has investigated these two SNPs in the Iranian populations, and according to the heterogeneity that exists, SNPs in communities should be examined separately.

Methods: This case-control study includes 82 people with prostate adenocarcinoma as cases and 96 people with benign prostatic hyperplasia (BPH) as controls. Genotyping of each participant was done by TETRA ARMS-PCR method and for statistical analysis chi-squared, Fisher’s exact logistic regression was used to find the SNPs associated with prostate cancer.

Result: The frequency of the polymorphisms rs4962416 and rs6465657 in the prostate adenocarcinoma group was evaluated compared to the BPH control group (p-value < 0.05%) to choose the meaningful SNP. For rs4962416, we didn’t find any meaningful association with prostatic cancer (p=0.402) but for rs6465657 there was a significant difference between genotype frequency (p=0.001).

Conclusion: rs6465657 polymorphism which is associated with prostate cancer, can be chosen as a biomarker for this cancer and there should be more investigation on this SNP as these results need to be confirmed in a larger population.

Keywords: Prostate cancer, polymorphism, single nucleotide polymorphisms, prostate-specific antigen, tumorigenesis.

« Previous Next »
Graphical Abstract

[1]
Lewis CL, Kistler CE, Amick HR, et al. Older adults’ attitudes about continuing cancer screening later in life: A pilot study interviewing residents of two continuing care communities. BMC Geriatr 2006; 6: 10.
[http://dx.doi.org/10.1186/1471-2318-6-10]
[2]
Engels EA, Pfeiffer RM, Ricker W, Wheeler W, Parsons R, Warren JL. Use of surveillance, epidemiology, and end results-medicare data to conduct case-control studies of cancer among the US elderly. Am J Epidemiol 2011; 174(7): 860-70.
[http://dx.doi.org/10.1093/aje/kwr146] [PMID: 21821540]
[3]
Sadjadi A, Nooraie M, Ghorbani A, et al. The incidence of prostate cancer in Iran: Results of a population-based cancer registry. Arch Iran Med 2007; 10(4): 481-5.
[PMID: 17903053]
[4]
Hosseini SY, Moharramzadeh M, Ghadian AR, Hooshyar H, Lashay AR, Safarinejad MR. Population-based screening for prostate cancer by measuring total serum prostate-specific antigen in Iran. Int J Urol 2007; 14(5): 406-11.
[http://dx.doi.org/10.1111/j.1442-2042.2006.01729.x] [PMID: 17511722]
[5]
Rafimanesh H, Ghoncheh M, Salehinia H, Mohammadian HA. Epidemiology of prostate cancer and its incidence trends in Iran. Journal of Sabzevar Univ Med Sci 2016; 232: 320-7.
[6]
Beikzadeh B, Angaji SA, Abolhasani M. Association study between common variations in some candidate genes and prostate adenocarcinoma predisposition through multi-stage approach in Iranian population. BMC Med Genet 2020; 21(1): 81.
[http://dx.doi.org/10.1186/s12881-020-01014-0] [PMID: 32295536]
[7]
Mei W, Lin X, Kapoor A, Gu Y, Zhao K, Tang D. The contributions of prostate cancer stem cells in prostate cancer initiation and metastasis. Cancers 2019; 11(4): 434.
[http://dx.doi.org/10.3390/cancers11040434] [PMID: 30934773]
[8]
Wang S, Wang N, Yu B, et al. Circulating IGF-1 promotes prostate adenocarcinoma via FOXO3A/BIM signaling in a double-transgenic mouse model. Oncogene 2019; 38(36): 6338-53.
[http://dx.doi.org/10.1038/s41388-019-0880-9] [PMID: 31312023]
[9]
Nasehi F, Sazgar H, Jahromi NZ. The effect of single-nucleotide polymorphism rs141831067 in Dehydrofolate reductase gene on response to methotrexate in patients with prostate cancer. New Cell Mol Biotechnol J 2019; 935: 83-92.
[10]
Benabdelkrim M, Djeffal O, Berredjem H. GSTM1 and GSTT1 polymorphisms and susceptibility to prostate cancer: a case-control study of the Algerian population. Asian Pac J Cancer Prev 2018; 19(10): 2853-8.
[PMID: 30362312]
[11]
Chen J, Miao L, Jin G, et al. TGFBR1 tagging SNPs and gastric cancer susceptibility: A two-stage case-control study in chinese population. Mol Carcinog 2014; 53(2): 109-16.
[http://dx.doi.org/10.1002/mc.21954] [PMID: 22911926]
[12]
Zhang S, Tang W, Ding G, et al. Variant TP53BP1 rs560191 G>C is associated with risk of gastric cardia adenocarcinoma in a Chinese Han population. Chin J Cancer Res 2015; 27(2): 156-62.
[PMID: 25937777]
[13]
Beikzadeh B, Angaji SA, Abolhasani M. Association between rs2735839 and serum prostate-specific antigen level regarding risk of prostate cancer in iranian population. Avicenna J Clin Med 2019; 26(1): 12-9.
[http://dx.doi.org/10.29252/ajcm.26.1.12]
[14]
Vaheb M. The evaluation of rs11614913 polymorphism in MIR196A2 gene and the risk of prostate cancer in chaharmahal and Bakhtiari province, Iran. J Isfahan Med Sch 2019; 37(527): 535-41.
[15]
Benafif S, Kote-Jarai Z, Eeles RA. A review of prostate cancer genome-wide association studies (GWAS). Cancer Epidemiol Biomarkers Prev 2018; 27(8): 845-57.
[http://dx.doi.org/10.1158/1055-9965.EPI-16-1046] [PMID: 29348298]
[16]
Matejcic M, Saunders EJ, Dadaev T, et al. Germline variation at 8q24 and prostate cancer risk in men of European ancestry. Nat Commun 2018; 9(1): 4616.
[http://dx.doi.org/10.1038/s41467-018-06863-1] [PMID: 30397198]
[17]
Allemailem KS, Almatroudi A, Alrumaihi F, et al. Single nucleotide polymorphisms (SNPs) in prostate cancer: its implications in diagnostics and therapeutics. Am J Transl Res 2021; 13(4): 3868-89.
[PMID: 34017579]
[18]
Guy M, Kote-Jarai Z, Giles GG, et al. Identification of new genetic risk factors for prostate cancer. Asian J Androl 2009; 11(1): 49-55.
[http://dx.doi.org/10.1038/aja.2008.18] [PMID: 19050691]
[19]
Tao S, Wang Z, Feng J, et al. A genome-wide search for loci interacting with known prostate cancer risk-associated genetic variants. Carcinogenesis 2012; 33(3): 598-603.
[http://dx.doi.org/10.1093/carcin/bgr316] [PMID: 22219177]
[20]
Takayama K, Horie-Inoue K, Katayama S, et al. Androgen-responsive long noncoding RNA CTBP1-AS promotes prostate cancer. EMBO J 2013; 32(12): 1665-80.
[http://dx.doi.org/10.1038/emboj.2013.99] [PMID: 23644382]
[21]
Wang Q, Li W, Zhang Y, et al. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 2009; 138(2): 245-56.
[http://dx.doi.org/10.1016/j.cell.2009.04.056] [PMID: 19632176]
[22]
Ryan CJ, Tindall DJ. Androgen receptor rediscovered: The new biology and targeting the androgen receptor therapeutically. J Clin Oncol 2011; 29(27): 3651-8.
[http://dx.doi.org/10.1200/JCO.2011.35.2005] [PMID: 21859989]
[23]
Albertsen PC. PSA and the conservative treatment of early prostate cancer. Arch Ital Urol Androl 2006; 78(4): 152-3.
[PMID: 17269621]
[24]
Mousavi SM. Toward prostate cancer early detection in Iran. Asian Pac J Cancer Prev 2009; 10(3): 413-8.
[PMID: 19640184]
[25]
Reza HS, Ali Z, Tara H, Ali B. Age-specific reference ranges of prostate-specific antigen in the elderly of Amirkola: A population-based study. Asian J Urol 2021; 8(2): 183-8.
[http://dx.doi.org/10.1016/j.ajur.2020.03.001] [PMID: 33996474]
[26]
Pakzad R, Rafiemanesh H, Ghoncheh M, et al. Prostate cancer in Iran: Trends in incidence and morphological and epidemiological characteristics. Asian Pac J Cancer Prev 2016; 17(2): 839-43.
[http://dx.doi.org/10.7314/APJCP.2016.17.2.839] [PMID: 26925689]
[27]
Rafi Menesh H, Ghancheh M, Salehi Niya H, Mohammadian Hefeshjani A. Epidemiology of prostate cancer and the trend of changes in its incidence in Iran. Asrar Journal of Sabzevar University of Medical Sciences 2015; 5(2): 23-9.
[28]
Harries LW, Perry JRB, McCullagh P, Crundwell M. Alterations in LMTK2, MSMB and HNF1B gene expression are associated with the development of prostate cancer. BMC Cancer 2010; 10(1): 315.
[http://dx.doi.org/10.1186/1471-2407-10-315] [PMID: 20569440]
[29]
Yadav S, Anbalagan M, Baddoo M, et al. Somatic mutations in the DNA repairome in prostate cancers in African Americans and Caucasians. Oncogene 2020; 39(21): 4299-311.
[http://dx.doi.org/10.1038/s41388-020-1280-x] [PMID: 32300177]
[30]
Poulsen MH, Feddersen S, Albitar M, et al. A prospective study of a urine and plasma biomarker test for the prediction of gleason ≥3 + 4 prostate cancer in a mixed cohort. Scand J Urol 2020; 54(4): 323-7.
[http://dx.doi.org/10.1080/21681805.2020.1782979] [PMID: 32608296]
[31]
Beltran H, Romanel A, Conteduca V, et al. Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer. J Clin Invest 2020; 130(4): 1653-68.
[http://dx.doi.org/10.1172/JCI131041] [PMID: 32091413]
[32]
Aslan R, Alp HH, Eryılmaz R, et al. Can the irisin be a biomarker for prostate cancer? A case control study. Asian Pac J Cancer Prev 2020; 21(2): 505-9.
[http://dx.doi.org/10.31557/APJCP.2020.21.2.505] [PMID: 32102531]
[33]
Liu Z, Zhong J, Cai C, Lu J, Wu W, Zeng G. Immune-related biomarker risk score predicts prognosis in prostate cancer. Aging 2020; 12(22): 22776-93.
[http://dx.doi.org/10.18632/aging.103921] [PMID: 33197890]
[34]
Shah K, Bradbury NA. Lemur Tyrosine Kinase 2, a novel target in prostate cancer therapy. Oncotarget 2015; 6(16): 14233-46.
[http://dx.doi.org/10.18632/oncotarget.3899] [PMID: 26008968]
[35]
Wang NN, Wang JY, Shi XH, et al. Association of TET2, LMTK2 and FAM84B gene expression with prostate cancer risk in Chinese patients. Chin J Oncol 2013; 35: 262-7.
[36]
Shui IM, Lindström S, Kibel AS, et al. Prostate Cancer (PCa) risk variants and risk of fatal PCa in the national cancer institute breast and prostate cancer cohort consortium. Eur Urol 2014; 65(6): 1069-75.
[http://dx.doi.org/10.1016/j.eururo.2013.12.058] [PMID: 24411283]
[37]
Eeles RA, Kote-Jarai Z, Giles GG, et al. Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet 2008; 40(3): 316-21.
[http://dx.doi.org/10.1038/ng.90] [PMID: 18264097]
[38]
Thomas G, Jacobs KB, Yeager M, et al. Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet 2008; 40(3): 310-5.
[http://dx.doi.org/10.1038/ng.91] [PMID: 18264096]
[39]
Takayama K, Suzuki T, Fujimura T, et al. CtBP2 modulates the androgen receptor to promote prostate cancer progression. Cancer Res 2014; 74(22): 6542-53.
[http://dx.doi.org/10.1158/0008-5472.CAN-14-1030] [PMID: 25228652]
[40]
Zhang P, Tillmans LS, Thibodeau SN, Wang L. Single-nucleotide polymorphisms sequencing identifies candidate functional variants at prostate cancer risk loci. Genes 2019; 10(7): 547.
[http://dx.doi.org/10.3390/genes10070547] [PMID: 31323811]

Rights & Permissions Print Cite
Article Metrics
16
2
© 2024 Bentham Science Publishers | Privacy Policy